comparemela.com

Latest Breaking News On - Mablink - Page 1 : comparemela.com

Mablink Bioscience Announces a €31 Million Series A Funding Round Led by Sofinnova Partners and Mérieux Equity Partners

The financing will enable the company to advance its lead candidate to the clinic and to build a pipeline of next-generation antibody-drug conjugates (ADCs)Its proprietary ADC technology opens the door

France generalCity ofUnited kingdomJean guillaume lafayFondation fournier majoieMablink adcsGraziano seghezziAlpha fraMablink bioscienceKostenloser wertpapierhandelFlorian denisEurope venture fundSofinnova partnersEquity partnersChief executive officerManaging partner

EV Technology Group Underpins Ambition to Grow With Plans

TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) EV Technology Group Ltd. (the “Company” or “EV Technology Group”) (OTCQB: EVTGF, NEO: EVTG, DE: B96A),.

United kingdomWouter witvoetSilverstone technology clusterEv technology group of fablink holdingsDev technology groupAutomotive divisionEv technology group centre of excellenceGlobe newswire ev technology group ltdFablink group holdings limitedStreamline automotive divisionStreamline automotiveAequitas neo exchange evtgV technology group incDev technology group

EV TECHNOLOGY GROUP INC : EV Technology Group Announces Agreement to Acquire Up to 100% of Fablink Group, Spearheading Future Global Growth

Hear from EV Technology Group CEO Wouter Witvoet on the Acquisition: https://bit.ly/3zvEGcm Transaction Highlights: EV Technology Group (NEO: EVTG) (OTCQB: EVTGF) (DE: B96A) announces that it has

United kingdomFablink technologieRachael damoreWouter witvoetRichard westleyDev technology groupCompany the commonFablink groupFablink group holdingsCommon shares of the companyFablink group holdings limitedFablink group the definitive agreementGlobe newswire ev technology group ltdDefinitive agreementBritish tierCommon shares

Mablink Bioscience S A S : Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy

Emergence Therapeutics obtains the rights to develop a novel antibody-drug conjugate using Mablink Bioscience's proprietary PSARlink drug-linker technology. Mablink Bioscience S.A.S. a biotechnology

Nordrhein westfalenJean guillaume lafayKostenloser wertpapierhandelMarc lopezMablink bioscienceMarseille universitHeidelberg pharmaCancer research centerDrug administrationHeidelberg pharma researchHeidelberg pharma research gmbEmergence therapeuticsGuillaume lafayWhile mablink bioscienceAix marseille universitHeidelberg pharma research gmbh

vimarsana © 2020. All Rights Reserved.